Tividenofusp alfa · Avlayah
Protein / enzyme therapeutic
Evidence outlook
Accelerated approval: Mucopolysaccharidosis Type II
Accelerated approval is granted on surrogate endpoints; confirmatory clinical benefit is being verified in ongoing trials. Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05371613 NCT05371613 · Mucopolysaccharidosis Type II Registry: NCT05371613 | 2/3 | Ratio to baseline in cerebrospinal fluid (CSF) heparan sulfate (HS) concentration (Cohort A) (24 weeks); Change from baseline in the Vineland Adaptive Behavior Scale, Third Edition (Vineland-3)(Cohort A) (96 weeks) 2027-12 | In progress: results expected 1 Dec 2027 | not yet graded | link ↗ |
View 1 more trial
NCT04251026 NCT04251026 · Mucopolysaccharidosis Type II Registry: NCT04251026 | 1/2 | Incidence and severity of treatment-emergent adverse events (TEAEs) (24 weeks, 104 weeks, and 357 weeks); Change from baseline in urine total glycosaminoglycan (GAG) concentrations (24 weeks, 104 weeks, and 357 weeks); Incidence and severity of infusion-related reactions (IRRs) (24 weeks, 104 weeks, and 357 weeks); Change from baseline in concomitant medications (24 weeks, 104 weeks, and 357 weeks) 2031-02 | In progress: results expected 1 Feb 2031 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2/3 (2)
What this study did
What this study did
Phase 1/2 (1)
What this study did
Competitive landscape
Other Iduronate-2-sulfatase (IDS) drugs
Clemidsogene lanparvovec. Compare all 2 Iduronate-2-sulfatase (IDS) drugs
1 other tracked programme targets this mechanism, none of them ahead of this one.
This drug's own stage for Mucopolysaccharidosis Type II: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tividenofusp Alfa (Avlayah): this drug | Approved | Protein / enzyme therapeutic | Iduronate-2-sulfatase (IDS) | not yet graded | No reviewed efficacy summary in this indication | |
| Clemidsogene Lanparvovec | Phase 3 | Gene therapy / editing | Iduronate-2-sulfatase (IDS) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Avlayah (Tividenofusp alfa) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
2031 (1)
February 2031 (1)
What to watch
Regulatory and conference events
(6)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent